<DOC>
	<DOCNO>NCT00207727</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety CNTO 1275 patient Multiple Sclerosis</brief_summary>
	<brief_title>A Safety Efficacy Study CNTO1275 Patients With Multiple Sclerosis</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) life-long disease usually start young adult . In MS , inflammation damage nerve cell occur brain spinal cord . Symptoms MS quite variable may range mild severe short long lasting . People MS may wide variety symptom range mild disabling . Some thesymptoms MS include visual disturbance double vision , weakness arm legs , difficulty coordination , fatigue , change sensation numbness tingle , difficulty concentration memory.The drug test research study antibody call CNTO 1275 . Antibodies natural substance make body stick react substance body may cause disease . The body make antibody mainly fight infection . CNTO 1275 antibody manufacture laboratory . In test tube , CNTO 1275 stick block activity naturally occur substance body call interleukin 12 ( IL-12 ) .Higher normal level IL-12 find people MS. CNTO 1275 test animal condition similar MS . In animal , IL-12 over-produced.Animals treat CNTO 1275 show decrease symptom condition.The purpose study well understand safety effectiveness CNTO 1275 people relapsing-remitting MS Patients receive subcutaneous injection 30 , 100 , 200 mg CNTO 1275 placebo Weeks 0 , 1 , 2 , 3 , 7 , 11 , 15 , 19 100 mg week 0,1,2,3,11 19 placebo wks 7 15 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have definite diagnosis Relapsing remit Multiple Sclerosis Have history least 1 follow : . A minimum 2 relapse MS within previous 2 year within 1month period prior screen . b . A relapse MS within previous 6 month within 1monthperiod prior screen Have CNS disease ( eg , CNS lymphoma , systemic lupus erythematous ) Have significant bulbar involvement MS neurologic deficit Have decubitus ulcer Have receive immunomodulatory therapy within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>